SCHEMBL5166145

SCHEMBL5166145

O=C(O)c1cccc(N2C(=O)c3cc(-n4cccc4)cc4cc(-n5cccc5)cc(c34)C2=O)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.65
MEN1 O00255 6/20 0.65
L3MBTL1 Q9Y468 3/20 0.65
POLB P06746 2/20 0.65
CASP6 P55212 1/20 0.65
TYMS P04818 1/20 0.54
RXFP1 Q9HBX9 2/20 0.54
ALDH1A1 P00352 2/20 0.54
KDM4E B2RXH2 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.53
CA12 O43570 1/20 0.50
CA9 Q16790 1/20 0.50
MAPK1 P28482 1/20 0.48
S100B P04271 1/20 0.48
MAPT P10636 1/20 0.47
RECQL P46063 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.45
PARP1 P09874 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5158766 0.83 KMT2A (0.66) KMT2AMEN1L3MBTL1POLBCASP6
SCHEMBL1514286 0.82 L3MBTL1 (0.73) KMT2AMEN1L3MBTL1POLBCASP6
SCHEMBL14172750 0.80 KMT2A (0.72) KMT2AMEN1L3MBTL1POLBCASP6
SCHEMBL5167037 0.79 MEN1 (1.00) KMT2AMEN1L3MBTL1POLBCASP6
SCHEMBL29549557 0.78 TYMS (0.71) KMT2AMEN1L3MBTL1POLBCASP6
SCHEMBL7825377 0.78 TYMS (0.71) KMT2AMEN1L3MBTL1POLBCASP6
SCHEMBL594234 0.78 AOC2 (0.64) KMT2AMEN1L3MBTL1POLBCASP6
SCHEMBL29671334 0.78 AOC2 (0.64) KMT2AMEN1L3MBTL1POLBCASP6
SCHEMBL5159288 0.78 MEN1 (0.60) KMT2AMEN1L3MBTL1POLBCASP6
SCHEMBL14510297 0.77 KMT2A (0.59) KMT2AMEN1L3MBTL1POLBCASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US claimed
WO-2007030939-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO claimed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
WO-2007030939-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 KMT2A 4267/4885MEN1 3865/4885L3MBTL1 4441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.